This Phase 1 study will evaluate PDE10 enzyme occupancy using Positron Emission Tomography after a single dose of PF-02545920 in Healthy male volunteers.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
9
Subject will receive a single dose of 20 mg PF-02545920.
The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg. This cohort is optional.
The dose will be selected based on the results obtained for Cohort 1 and cohort 2.
Karolinska Trial Alliance (KTA) M62
Huddinge, Stockholm County, Sweden
Central PDE10A enzyme occupancy values in the striatum.
Using Positron Emission Tomography and a radiotracer (MNI-659) for PF-02545920, the central PDE10A enzyme occupancy values will be measured in the striatum at different single oral doses of PF-02545920.
Time frame: Day 10
Central PDE10A enzyme occupancy values in the globus pallidus, in the caudate and in the putamen (separately).
Using Positron Emission Tomography and a radiotracer (MNI-659) for PF-02545920, central PDE10A enzyme occupancy values in the globus pallidus, in the caudate and in the putamen be measured (separately) at different single oral doses of PF-02545920.
Time frame: Day 10
Maximum Observed Plasma Concentration (Cmax)
Cmax for serum PF-02545920 during the post-dose positron emission tomography (PET) scan.
Time frame: Day 10
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Tmax for serum PF-02545920 during the post-dose positron emission tomography (PET) scan.
Time frame: Day 10
Average serum concentration
Average serum 02545920 during the post-dose positron emission tomography (PET) scan.
Time frame: Day 10
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.